Cambridge headquartered AstraZeneca and its global biologics R & D arm MedImmune, plan to develop new therapies for respiratory disease through a five-year collaboration with Munich-based Ethris GmbH.
The Cambridge UK duo will pay Ethris €25 million upfront, plus research funding; Ethris is also eligible for future R & D milestones, including sales-related royalties on commercialisation.
{iframe}http://www.businessweekly.co.uk/news/biomedtech/astrazeneca-and-medimmune-pay-germans-%E2%82%AC25m-upfront-respiratory-disease-edge{/iframe}